Imedex is presenting the 20th Edition of it’s Annual Conference on Perspectives in Thoracic Oncology, which will take on November 20 – 21, 2015 in New York, United States at the Grand Hyatt New York Hotel.
Perspectives in Thoracic Oncology has become the premier source for updates in thoracic oncology; we readily recognize the burgeoning need among thoracic oncology clinicians and researchers for the latest information on the complex biology and treatment of lung cancer. This conference provides a forum to update your knowledge in the field, confirm your current practice and receive valuable take-home information on exciting new screening and staging modalities, management approaches and emerging treatment options.
Significant Impact on Clinical Practice Nearly 200 physicians, nurses, and other healthcare professionals attend Perspectives in Thoracic Oncology annually. Past participants value the scope and depth of the information on disease biology, management, and research presented, and many return year after year for the newest updates.
Distinguished Faculty and Networking Opportunities In this educational setting, you will have valuable opportunities to interact with your colleagues and learn from renowned faculty, key thought leaders in thoracic oncology, as well as network with the diverse mix of oncologists, surgeons, and pulmonologists who attend.
- Will “liquid biopsy” replace conventional tissue-based sampling?
- Curtailing smoking addiction: How do we “slay the deadly beast?”
- Perspective on the Updated TNM Classification: Is there a role for histology or markers?
- Managing the “Neglected” Mediastinum and Other surgical issues
- Locally Advanced NSCLC: Does choice of systemic agents and sequencing make a difference in combined modality therapy?
- Strategies for locally advanced NSCLC: Therapeutic debate – Bimodality approach – Trimodality approach
- Novel forms of radiation: Can Technology Trump Biology?
- Update on rare species in the thoracic “wilds”: Carcinoid, large cell neuroendocrine, and thymomas
- Squamous cell carcinoma: Changing face of 1st and 2nd line therapy
- Optimal therapy for special populations (elderly and PS2 patients)
- Management of CNS metastases (SRS vs WBRT, hippocampal sparing, role of memantine, etc.)
- Advances in esophageal cancer: Current and future strategies
- Point-Counterpoint: What is best management of MPM? Systemic Therapy? Combined modality?
- EGFR inhibitors in mutation patients: Current therapeutic strategies in the frontline setting
- Managing progression in EGFR-mutant NSCLC patients: What will be the impact of 2nd and 3rd Generation TKIs?
- Therapeutic guideposts in maintenance therapy: Switch? Continue? vs. Observe?
- Targeting angiogenesis in NSCLC
- Palliative care does not equal hospice
- Communicating with patients and families: Managing expectations as Hope and Reality Collide
- Combating Cachexia: New Approaches
- Panel discussion on how to conduct family meetings and end of life conversations
- The therapeutic implications of EML4/ALK, ROS-1 and other actionable biomarkers
- Targeting HER2, BRAF, KRAS, MET
- SCLC: Therapeutic Progress or Mirage?
- Biologic Basis of Immunotherapy in Lung cancer
- Targeting the immune system with checkpoint inhibitors
- Expanding Beyond the Checkpoints: new vaccines, and other immunologic strategies in the management of NSCLC
Who Should Attend
This educational activity is designed to meet the educational needs of medical and radiation oncologists, thoracic surgeons, nurses, diagnostic radiologists, pathologists, pulmonologists, researchers and other healthcare professionals interested in the care and treatment of patients with thoracic malignancies.
- Michelle Alonso-Basanta, MD, PhD – University of Pennsylvania, Philadelphia, Pennsylvania
- Laura Jean Bierut, MD – Washington University School Of Medicine, St. Louis, Missouri
- Philip D. Bonomi, MD – Rush Medical College, Chicago, Illinois
- Roger B. Cohen, MD – University of Pennsylvania, Philadelphia, Pennsylvania
- Beth Eaby-Sandy, CRNP, OCN – Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania
- Tracey Evans, MD – University of Pennsylvania, Philadelphia, Pennsylvania
- William K. Evans, MD – McMaster University, Ontario, Canada
- Andrew R. Haas, MD – University of Pennsylvania Medical Center, Philadelphia, Pennsylvania
- Ranee Mehra, MD – Fox Chase Cancer Center, Philadelphia, Pennsylvania
- Paul K. Paik, MD – Memorial Sloan-Kettering Cancer Center, New York, New York
- Harvey I. Pass, MD – NYU Langone Medical Center, New York, New York
- Gregory J. Riely, MD, PhD – Memorial Sloan Kettering Cancer Center, New York, New York
- Helen J. Ross, MD – Mayo Clinic, Scottsdale, Arizona
- Gerard A. Silvestri, MD, MS, FCCP – Medical University of South Carolina, Charleston, South Carolina
- Charles B. Simone, MD – University of Pennsylvania, Philadelphia, Pennsylvania
- Mark A. Socinski, MD – University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania
Imedex®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
This activity has been approved for 14 AMA PRA Category 1 Credit™.